RT Journal Article
SR Electronic
T1 Brain network hypersensitivity underlies pain crises in sickle cell disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.08.23296715
DO 10.1101/2023.10.08.23296715
A1 Joo, Pangyu
A1 Kim, Minkyung
A1 Kish, Brianna
A1 Nair, Vidhya Vijayakrishnan
A1 Tong, Yunjie
A1 Harte, Steven E
A1 Harris, Richard E
A1 Lee, UnCheol
A1 Wang, Ying
YR 2023
UL http://medrxiv.org/content/early/2023/10/09/2023.10.08.23296715.abstract
AB Sickle cell disease (SCD) is a genetic disorder causing blood vessel blockages and painful Vaso-occlusive crises (VOCs). VOCs, characterized by severe pain due to blocked blood flow, are recurrent and unpredictable, posing challenges for preventive strategies. In this study we propose explosive synchronization (ES), a phenomenon characterized by abrupt brain network phase transitions, as a novel approach to address this challenge. We hypothesized that the accumulated disruptions in the brain network induced by SCD might lead to strengthened ES and hypersensitivity. We explored ES’s relationship with patient reported outcome measures (PROMs) and VOCs by analyzing EEG data from 25 SCD patients and 18 matched controls. SCD patients exhibited significantly lower alpha wave frequency than controls. SCD patients under painful pressure stimulation showed correlation between frequency disassortativity (FDA), an ES condition, and three important PROMs. Furthermore, patients who had a higher frequency of VOCs in the preceding 12 months presented with stronger FDA. The timing of VOC occurrence relative to EEG recordings was significantly associated to FDA. We also conducted computational modeling on SCD brain network to study FDA’s role in network sensitivity. Stronger FDA correlated with higher responsivity and complexity in our model. Simulation under noisy environment showed that higher FDA could be linked to increased occurrence frequency of crisis. This study establishes connections between SCD pain and the universal network mechanism, ES, offering a strong theoretical foundation. This understanding will aid predicting VOCs and refining pain management for SCD patients.Competing Interest StatementSEH has consulted for Aptinyx, Memorial Sloan Kettering Cancer Institute, University of North Carolina-Chapel Hill, Indiana University, and University of Glasgow, and has received research funding from NIH, Arbor Medical Innovations, and Aptinyx. REH has received grant funding from Pfizer, Aptinyx, and Cerephex. and National Institutes of Health (NIH). The remaining authors declare no competing interests.Clinical TrialNCT05045820Funding StatementThis work was supported by NIH K99/R00 award (Grant # 4R00AT010012) and Indiana University Health – Indiana University School of Medicine Strategic Research Initiative funding to YW. UL was supported by NIGMS (R21GM143521).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Indiana University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.